New York, New York

Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

Registration Details

  • Early Registration: $75.00 (USD)
  • Early Registration ends: Monday, March 4, 2019
  • Preregistration: $95.00 (USD)
  • Preregistration ends: Monday, March 11, 2019
  • On-site Registration: $105.00 (USD)
  • On-site Registration ends: Monday, March 18, 2019
  • Fellow/Student Registration: $30.00 (USD)
  • Fellow/Student Registration ends: Monday, March 18, 2019

Course Chairs

Gerald H. Friedland, MD
Yale University School of Medicine
Paul A. Volberding, MD
University of California San Francisco


Roy M. Gulick, MD, MPH
Weill Cornell Medicine
Michael S. Saag, MD
University of Alabama at Birmingham


March 18, 2019 - 8:00 AM


March 18, 2019 - 5:00 PM


New York University School of Law
Vanderbilt Hall - Tishman Auditorium
40 Washington Square South
New York
New York
United States

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Apply newly available data to antiretroviral strategies for management of established HIV infection
  • Identify situations in which antiretroviral regimens should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Increase primary prevention through use of preexposure prophylaxis (PrEP) by determining which patients might benefit from PrEP and initiate and monitor use of PrEP for uninfected patients at risk for HIV infection
  • Describe the most current data on investigational new drugs and approaches
  • Incorporate selected aspects of primary care for individuals with HIV infection, especially in the aging population, which may include:
    • Screening for cancer
    • Sexually transmitted infections and opportunistic infections screening, treatment, and prevention
    • Renal disease
    • Cardiovascular disease
    • Bone disease
    • Endocrine disorders
    • Neurocognitive disorders

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is eligible for AMA PRA Category 1 Credits™; see final activity announcement for specific details.


ABIM MOCThis activity is eligible for ABIM MOC Points; see final activity announcement for specific details.

Nursing Credits

This activity is eligible for ANCC and pharmacotherapy credits; see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoThis activity is eligible for ACPE credit; see final CPE activity announcement for specific details.

Grant Support

Requests for educational grants have been made to commercial companies with competing products. Information on grant support will be posted on the IAS–USA website as it becomes available.

Physician Payment Sunshine Act (“Sunshine Act” or “Open Payment”)

In 2014, the Physician Payment Sunshine Act (“Sunshine Act” or “Open Payments”), a provision of the Affordable Care Act, was developed. According to the Centers for Medicare and Medicaid Services (CMS): “Open Payments is a national disclosure program that promotes transparency by publishing the financial relationships between the medical industry and healthcare providers (physicians and hospitals) on a publicly accessible website developed by CMS.” Until recently, CME activities that receive commercial support have been exempt from reporting payments for goods such as hosted meals. Attendee registration fees are used for all food and beverage expenses provided by IAS–USA at the activity.